Showing results (91-100 of 257) with videos related to
Sort By:
Pageof 26
Cancers|April 30, 2021
Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-UpNovella Pugliese, Marco Picardi, Roberta Della Pepa, et al.Annals of Hematology|January 8, 2021
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)Massimo Breccia, Simone Celant, Pier Paolo Olimpieri, et al.Journal of Clinical Medicine|August 26, 2023
Italian Physicians' Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA SurveyMassimo Breccia, Alfonso Piciocchi, Elisabetta Abruzzese, et al.Leukemia Research|August 19, 2007
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rateGiuliana Alimena, Massimo Breccia, Luigia Luciano, et al.Cancer Reports (Hoboken, N.J.)|April 25, 2024
Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patientsBianca Serio, Francesco Grimaldi, Lucia Ammirati, et al.Cancer Medicine|April 19, 2019
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosisNovella Pugliese, Claudia Giordano, Davide Nappi, et al.Haematologica|May 14, 2026
Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in ItalyMassimo Breccia, Alessandra Iurlo, Fabrizio Pane, et al.Frontiers in Immunology|November 19, 2025
Expression and prognostic value of FKBP51 in Hodgkin lymphomaSilvia Varricchio, Simona Romano, Daniela Russo, et al.Annals of Hematology|October 1, 2016
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinionMassimo Breccia, Patrizia Pregno, Paolo Spallarossa, et al.Acta Bio-Medica : Atenei Parmensis|July 29, 2017
Clinical pathway for patients with Chronic Myeloid Leukaemia: The Euriclea ProjectStefano Botti, Gianpaolo Gargiulo, Felice Bombaci, et al.Pageof 26